433 related articles for article (PubMed ID: 22504918)
1. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Welsch C; Jesudian A; Zeuzem S; Jacobson I
Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
[TBL] [Abstract][Full Text] [Related]
2. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
[TBL] [Abstract][Full Text] [Related]
3. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
4. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
5. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM; Jacobson IM
Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
[TBL] [Abstract][Full Text] [Related]
6. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
Kozielewicz D; Halota W; Dybowska D
Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Trembling PM; Tanwar S; Dusheiko GM
Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
[TBL] [Abstract][Full Text] [Related]
9. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
10. New developments in HCV therapy.
Kronenberger B; Zeuzem S
J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
[TBL] [Abstract][Full Text] [Related]
11. [Antiviral treatment of chronic hepatitis C].
Berger A
Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
[TBL] [Abstract][Full Text] [Related]
12. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
13. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
[TBL] [Abstract][Full Text] [Related]
14. Anemia management in patients with chronic viral hepatitis C.
Hynicka LM; Heil EL
Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
[TBL] [Abstract][Full Text] [Related]
15. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
Hézode C
Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
[TBL] [Abstract][Full Text] [Related]
16. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
Pol S; Corouge M; Mallet V; Sogni P
Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
[TBL] [Abstract][Full Text] [Related]
17. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
18. [Boceprevir: new possibilities for antiviral treatment of chronic hepatitis C].
Nikitin IG; Baĭkova IE; Gogova LM; Volynkina VM; Kisliakov VA
Ter Arkh; 2013; 85(2):76-84. PubMed ID: 23653945
[TBL] [Abstract][Full Text] [Related]
19. Telaprevir.
Prescrire Int; 2012 Apr; 21(126):93-6. PubMed ID: 22515133
[TBL] [Abstract][Full Text] [Related]
20. Directly acting antivirals against hepatitis C virus.
Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
